Valence 로고
인기
로그인
Loading data for GALDY — first visit, this takes a few seconds.

관심목록에 추가

GALDERMA GROUP AG

OTC Markets OTCPK: GALDY · 실시간 가격 · USD
41.66
-2.27 (-5.17%)
종가 기준: Aug 17, 2026, 8:00 PM

GALDERMA GROUP AG (GALDY) Stock Price, Analysis & Data

-5.17%

데이터 없음

매수호가n/a
시가총액48.57B
매출 (ttm)5.92B
순이익 (ttm)863M
베타-0.10
EPS (ttm)0.72
P/E (ttm)57.86
선행 P/E6.59
P/B (ttm)5.91
P/S (ttm)8.20
Earnings Daten/a
매도호가n/a
거래량19,964
평균 거래량 (20일)117,347
시가42.23
전일 종가43.93
일중 범위41.57 - 42.23
52주 범위32.96 - 46.31
애널리스트n/a
목표주가n/a
배당$0.09 (0.21%)
배당락일2026년 4월 27일

GALDY 소개

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 Aug 15, 2024
직원 수 7,676
상장 거래소 OTC Markets OTCPK
티커 GALDY
웹사이트 https://www.galderma.com
전체 기업 정보

재무 실적

2025년 GALDERMA GROUP의 매출은 5.24B로, 전년 4.44B 대비 18.04% 증가했습니다. 순이익은 613M로, 165.37% 증가했습니다.

재무제표
news image

2주 전 · Investing.com

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth f...

news image

3주 전 · GuruFocus.com

Galderma Group AG (GDERF) Half Year 2026 Earnings Call Highlights: Record Sales and Strategic ...

Galderma Group AG (GDERF) reports robust sales growth and strategic advancements, while navigating regulatory and market challenges.

news image

1개월 전 · The Wall Street Journal

Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S.

Shares dropped after the skincare group failed to secure approval for its latest antiwrinkle treatment, a potential rival to AbbVie’s Botox.

news image

1개월 전 · Investing.com

Galderma falls after FDA issues second setback for Botox rival

Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment Relabotulinumto...

news image

2개월 전 · Zacks

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

2 페이지 중 1